Xingyu Wu

Xingyu Wu

Auto-generated profile, based on publicly available information

Xingyu Wu

University of California San Diego 1 Moores Cancer Center San Diego, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Cancer Research
Verified
Journal Article
Closed access
KKKeiichi Koshizuka
Keiichi Koshizuka
XWXingyu Wu
Xingyu Wu
KSKuniaki Sato
Kuniaki Sato
PVPham Thuy Tien Vo
Pham Thuy Tien Vo
GMGosia M. Murawska
Gosia M. Murawska
JGJ.Silvio Gutkind
J.Silvio Gutkind
Genomic alterations converging on persistent activation of the PI3K/mTOR pathway represent one of the most frequently altered signaling circuitries in cancer. However, the clinical efficacy of mTOR inhibitors (mTORi) has been limited. In this study, we took advantage of the widespread activation of PI3K/mTOR signaling in head and neck squamous cell carcinoma (HNSCC) and the promising effects of mTORi in HNSCC experimental models and recent clinical trials to gain a mechanistic understanding of the antitumoral activity of mTORi. A genome-wide CRISPR screen revealed that treatment with mTORi promotes the autophagic degradation of ferritin (ferritinophagy), consequently increasing free intracellular iron, inducing lipid peroxidation, and ultimately driving cancer cell demise by ferroptosis. These findings provide a rationale for synergistic combinations repurposing approved drugs that disable cellular ferroptotic defense mechanisms. Together, this study provides a molecular framework underlying the antitumor activity of mTORi in HNSCC, thereby revealing multimodal precision therapies for HNSCC and many human malignancies displaying overactive PI3K/mTOR signaling. Significance: Inhibition of mTOR induces ferritinophagy that increases free iron and stimulates ferroptosis, suggesting that this axis could be harnessed to help predict responses and to develop rational combination therapies to overcome resistance.

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
YGYUSUKE GOTO
YUSUKE GOTO
KKKeiichi Koshizuka
Keiichi Koshizuka
TAToshinori Ando
Toshinori Ando
HIHiroki Izumi
Hiroki Izumi
XWXingyu Wu
Xingyu Wu
JGJ.Silvio Gutkind
J.Silvio Gutkind
The comprehensive genomic analysis of the head and neck squamous cell carcinoma (HNSCC) oncogenome revealed the frequent loss of p16INK4A (CDKN2A) and amplification of cyclin D1 genes in most human papillomavirus–negative HNSCC lesions. However, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown modest effects in the clinic. The aberrant activation of the PI3K/mTOR pathway is highly prevalent in HNSCC, and recent clinical trials have shown promising clinical efficacy of mTOR inhibitors (mTORi) in the neoadjuvant and adjuvant settings but not in patients with advanced HNSCC. By implementing a kinome-wide CRISPR/Cas9 screen, we identified cell-cycle inhibition as a synthetic lethal target for mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergism in HNSCC-derived cells in vitro and in vivo. Remarkably, we found that an adaptive increase in cyclin E1 (CCNE1) expression upon palbociclib treatment underlies the rapid acquired resistance to this CDK4/6 inhibitor. Mechanistically, mTORi inhibits the formation of eIF4G–CCNE1 mRNA complexes, with the consequent reduction in mRNA translation and CCNE1 protein expression. Our findings suggest that mTORi reverts the adaptive resistance to palbociclib. This provides a multimodal therapeutic option for HNSCC by cotargeting mTOR and CDK4/6, which in turn may halt the emergence of palbociclib resistance. Significance: A kinome-wide CRISPR/Cas9 screen identified cell-cycle inhibition as a synthetic lethal target of mTORis. A combination of mTORi and palbociclib, a CDK4/6-specific inhibitor, showed strong synergistic effects in HNSCC. Mechanistically, mTORis inhibited palbociclib-induced increase in CCNE1.

26 October 2024 in Cancer Prevention Research
Verified
Journal Article
Closed access
XWXingyu Wu
Xingyu Wu
SASendi Rafael Adame-Garcia
Sendi Rafael Adame-Garcia
KKKeiichi Koshizuka
Keiichi Koshizuka
PVPham Thuy Tien Vo
Pham Thuy Tien Vo
THThomas S. Hoang
Thomas S. Hoang
JGJ.Silvio Gutkind
J.Silvio Gutkind
Metformin administration has recently emerged as a candidate strategy for the prevention of head and neck squamous cell carcinoma (HNSCC). However, the intricate relationship between genetic alterations in HNSCC and metformin sensitivity is still poorly understood, which prevents the stratification of patients, harboring oral premalignant lesions that may benefit from the chemopreventive activity of metformin. In this study, we investigate the impact of prevalent mutations in HNSCC on response to metformin. Notably, we found that the expression of oncogenic HRAS mutants confers resistance to metformin in isogenic HNSCC cell systems, and that HNSCC cells harboring endogenous HRAS mutations display limited sensitivity to metformin. Remarkably, we found that metformin fails to reduce activation of the mTOR pathway in HRAS oncogene-expressing HNSCC cells in vitro and in vivo, correlating with reduced tumor suppressive activity. Mechanistically, we found that this process depends on the ability of HRAS to enhance glycolytic metabolism, thereby suppressing the requirement for oxidative phosphorylation to maintain the cellular energetic balance. Overall, our study revealed that HNSCC cells with oncogenic HRAS mutations exhibit diminished metformin sensitivity, thus shedding light on a potential mechanism of treatment resistance. This finding may also help explain the limited clinical responses to metformin in cancers with RAS mutations. Ultimately, our study underscores the importance of understanding the impact of the genetic landscape in tailoring precision cancer-preventive approaches in the context of HNSCC and other cancers that are characterized by the presence of a defined premalignant state, and therefore, are amenable to cancer interception strategies. Prevention Relevance: Our findings highlight the challenges of using metformin for cancer prevention in RAS-mutant cancers, where elevated glycolysis may reduce drug efficacy. This underscores the need to explore metformin’s potential in early, premalignant stages, before metabolic shifts render it less effective.

19 December 2025 in Cancer Prevention Research
Verified
Journal Article
Closed access
THThomas S. Hoang
Thomas S. Hoang
FFFarhoud Faraji
Farhoud Faraji
AMAmaya N. Mendez-Molina
Amaya N. Mendez-Molina
SASendi Rafael Adame-Garcia
Sendi Rafael Adame-Garcia
KSKuniaki Sato
Kuniaki Sato
JGJ.Silvio Gutkind
J.Silvio Gutkind
Head and neck squamous cell carcinoma (HNSCC) is among the 10 most common cancers worldwide and is associated with high morbidity and poor survival. Diminished HNSCC outcomes are often related to delayed diagnosis and treatment of occult progression of premalignant lesions, underscoring the need for effective and low-risk chemoprevention strategies. In this regard, metformin has shown promising clinical activity for HNSCC prevention. In this study, we performed a genome-wide CRISPR/Cas9 screen of metformin-treated HNSCC cells and identified the activation of PKA signaling as the top resistance pathway. We show that metformin mediates PKA activation in HNSCC cells and that PKA inhibition, when combined with metformin treatment, synergistically inhibits HNSCC growth. We found that metformin-induced PKA activation is mediated by a prostaglandin E2 autocrine loop, which can be blocked using cyclooxygenase-2 (COX2) inhibitors. Importantly, COX2 inhibition using nonsteroidal anti-inflammatory drugs (NSAID) combined with metformin treatment synergistically inhibits HNSCC cell growth and prevents the progression of oral premalignant lesions into invasive HNSCC in a model of tobacco-driven oral carcinogenesis. Together, these findings demonstrate that metformin and NSAID combination therapy may represent a promising therapeutic strategy for HNSCC chemoprevention. Prevention Relevance: Our findings reveal that using metformin for head and neck cancer chemoprevention leads to compensatory activation of a PKA-driven resistance mechanism that can be blocked by cotreatment with NSAIDs. These findings provide a rationale for combining metformin with NSAIDs as a precision head and neck cancer chemoprevention strategy.

29 July 2024
Verified
Other
Open access
PDF file
YGYUSUKE GOTO
YUSUKE GOTO
KKKeiichi Koshizuka
Keiichi Koshizuka
TAToshinori Ando
Toshinori Ando
HIHiroki Izumi
Hiroki Izumi
XWXingyu Wu
Xingyu Wu
JGJ.Silvio Gutkind
J.Silvio Gutkind
Combination of INK128 and palbociclib showed strong synergism in HNSCC cells in vitro

29 July 2024
Verified
Other
Open access
PDF file
YGYUSUKE GOTO
YUSUKE GOTO
KKKeiichi Koshizuka
Keiichi Koshizuka
TAToshinori Ando
Toshinori Ando
HIHiroki Izumi
Hiroki Izumi
XWXingyu Wu
Xingyu Wu
JGJ.Silvio Gutkind
J.Silvio Gutkind
CRISPR screening identified cell cycle pathway as synthetic lethal pathway for mTORi in HNSCC